(eClinicalMedicine) found that 52 weeks of once-weekly semaglutide reduced hip bone mineral density by 2.6% and lumbar spine density by 2.1% compared to placebo, with increased bone resorption and no compensatory increase in bone formation
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity in Diabetes: from Research to Clinical Practice: Volume 4 (ed
Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a Meta-analysis of the EXSCEL and FIGHT trials
While GLP-1 medications have a low intrinsic risk of hypoglycaemia when used alone, this risk increases when combined with insulin or sulfonylureas, which may require dose adjustment of these other medications
These benefits appear to result from weight loss, improved glycemic control, modest blood pressure reduction, and potential direct cardioprotective effectsnot from metabolic rate enhancement
GLP-1 agonists and dipeptidyl-peptidase IV inhibitors